GlassScriptPhysician profile
James C Mackenzie
NPI 1548251168
$3,348.28
in general payments reported to CMS, 2019-2025
12 companies · $521 in 2025
The $521 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $115 · 2021: $675 · 2022: $296 · 2023: $156 · 2024: $114 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,405.79 | 2019-2025 | Ozempic |
| Amgen INC. | $510.45 | 2019-2021 | |
| Lilly USA, LLC | $429.48 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $249.48 | 2025 | Fasenra, Airsupra |
| Amarin Pharma, INC. | $160.40 | 2019 | |
| Genzyme Corporation | $124.74 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.70 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $113.94 | 2024 | |
| Abbvie INC. | $54.80 | 2022-2023 | |
| Si-Bone, INC. | $40.32 | 2022 | |
| Pfizer INC. | $22.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mackenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.